Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497614 | 0.89 | CYP19A1 (0.34) | CYP19A1ERN1SIGMAR1 | |
| SCHEMBL5497620 | 0.89 | CYP19A1 (0.34) | CYP19A1ERN1SIGMAR1 | |
| SCHEMBL13863146 | 0.87 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL31080875 | 0.83 | ALDH1A1 (0.37) | FKBP1A | |
| SCHEMBL7123624 | 0.83 | ALDH1A1 (0.37) | FKBP1A | |
| SCHEMBL8145265 | 0.82 | CYP19A1 (0.34) | CYP19A1ERN1ELANECTSGSIGMAR1 | |
| SCHEMBL27190406 | 0.80 | TOP2A (0.34) | FKBP1A | |
| SCHEMBL8701755 | 0.79 | PSEN1 (0.41) | FKBP1A | |
| SCHEMBL8701756 | 0.79 | PSEN1 (0.41) | FKBP1A | |
| SCHEMBL5492451 | 0.78 | SIGMAR1 (0.31) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| US-7528126-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED | 2009-05-05 | — | — | US | disclosed |
| US-7265105-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| US-7265105-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| US-20070185073-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20060148788-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
| EP-0330108-B1 | 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5081237-A | Chemical intermediates for bactericides | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| US-4923857-A | CARBAPENICILLINS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-08 | — | — | US | disclosed |
| EP-0330108-A1 | 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | RNASE1, GTF3C3, CTRL | CYP19A1 884/4885ERN1 52/4885ELANE 935/4885 |
| US-20060148788-A1 | Pyrrolobenzodiazepines | HCRTR2, MCHR2, CHRM5 | CYP19A1 3730/4885ERN1 3829/4885ELANE 4875/4885 |
| US-20070185073-A1 | Pyrrolobenzodiazepines | H1-10, DRD1, AVPR1B | CYP19A1 1236/4885ERN1 3824/4885ELANE 4112/4885 |
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | CYP19A1 3158/4885ERN1 2803/4885ELANE 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.